
Journal of Diabetes and Its Complications xxx (xxxx) xxx



Contents lists available at ScienceDirect

Journal of Diabetes and Its Complications



journal homepage: WWW.JDCJOURNAL.COM

Mannose-binding lectin and risk of infections in type 2 diabetes: A Danish cohort study

Anne Gedebjerg ^{a,b,*}, Reimar Wernich Thomsen ^a, Alisa Devedzic Kjaergaard ^a, Rudi Steffensen ^c, Jens Steen Nielsen ^{d,e}, Jørgen Rungby ^{f,g}, Søren Gunnar Friborg ^h, Ivan Brandslund ⁱ, Steffen Thiel ^j, Henning Beck-Nielsen ^{d,h}, Henrik Toft Sørensen ^a, Troels Krarup Hansen ^k, Mette Bjerre ¹

^a Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark

^b Danish Diabetes Academy, Odense University Hospital, Odense, Denmark

^c Department of Immunology, Aalborg University Hospital, Aalborg, Denmark

- ^d DD2, Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark
- ^e Department of Clinical Research, University of Southern Denmark, Odense, Denmark

^f Department of Endocrinology IC, Bispebjerg University Hospital, Copenhagen, Denmark

^g Copenhagen Center for Translational Research, Bispebjerg University Hospital, Copenhagen, Denmark

^h Diabetes Research Centre, Department of Endocrinology, Odense University Hospital, Odense, Denmark

ⁱ Department of Biochemistry, Lillebaelt Hospital, Vejle, Denmark

^j Department of Biomedicine, Aarhus University, Aarhus, Denmark

^k Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark

¹ Medical Research Laboratory, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

ARTICLE INFO

Article history: Received 5 November 2020 Received in revised form 11 January 2021 Accepted 15 January 2021 Available online xxxx

Keywords: Association Cohort study Epidemiology Infection Mannose-binding lectin Type 2 diabetes

ABSTRACT

Aims: In individuals at increased risk of infections, e.g., patients with type 2 diabetes, low MBL may have detrimental effects. We used the Mendelian randomization principle to examine whether genetically low MBL is a risk factor for developing infections in patients with type 2 diabetes.

Methods: Serum MBL (n = 7305) and MBL genotype (n = 3043) were determined in a nationwide cohort of patients with new type 2 diabetes and up to 8 years follow-up for hospital-treated infections and community-based antimicrobial prescriptions. The associations were examined in spline and Cox regression analyses.

Results: 1140 patients (16%) were hospitalized with an infection and 5077 patients (70%) redeemed an antimicrobial prescription. For low ($\leq 100 \,\mu$ g/L) versus intermediate (101–1000 μ g/L) serum MBL concentration, the adjusted hazard ratios (aHRs) were 1.13(95% confidence interval, 0.96–1.33) for any hospital-treated infections and 1.19(1.01–1.41) for bacterial infections. Low MBL expression genotype was not associated with risk of any hospital-treated infections except for diarrheal diseases (aHR 2.23[1.04–4.80]). Low MBL expression genotype, but not low serum MBL, was associated with increased risk for antimicrobial prescriptions (aHR 1.18 [1.04–2.34] and antibacterial prescriptions 1.20[1.05–1.36]).

Conclusions: Low MBL is a weak causal risk factor for developing infections in patients with type 2 diabetes. © 2021 Elsevier Inc. All rights reserved.

1. Introduction

Mannose-binding lectin (MBL) is a plasma protein that plays an important role in innate immunity,¹ as it recognizes and binds to carbohydrate structures of a variety of pathogens, e.g., bacteria, viruses, and fungi.² Around 5% of Caucasians have an inherited MBL deficiency leading to reduced plasma levels of MBL protein.³ A number of clinical studies have reported an association between serum MBL deficiency and elevated risk of lower respiratory tract infections.^{4–10} In contrast, a large cohort study found only a weak association between low MBL

* Corresponding author at: Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Alle 43-45, DK-8200 Aarhus N, Denmark.

E-mail address: aged@clin.au.dk (A. Gedebjerg).

https://doi.org/10.1016/j.jdiacomp.2021.107873 1056-8727/© 2021 Elsevier Inc. All rights reserved. genotypes and risk of hospitalization with infection among adults, arguing against a strong causal role of MBL for severe infections in the general population.³ In individuals already at increased risk of infections due to an impaired immune system, e.g., patients with cancer or autoimmune diseases including diabetes,^{11–15} low MBL may be clinically important. Patients with type 2 diabetes have rates of antibiotic prescriptions and hospital-treated infections that are approximately 50% higher than for the general population,¹⁶ and more severe infection outcomes including during the current COVID-19 pandemic.¹⁷

We therefore examined the hypothesis that low MBL is associated with increased risk of infection in 7588 Danish patients with early type 2 diabetes followed for up to 8 years, investigating both serum MBL levels and MBL expression genotypes. According to the Mendelian randomization principle, if both low serum MBL and low MBL genotype

Please cite this article as: A. Gedebjerg, R.W. Thomsen, A.D. Kjaergaard, et al., Mannose-binding lectin and risk of infections in type 2 diabetes: A Danish cohort study, Journal of Diabetes and Its Complications, https://doi.org/10.1016/j.jdiacomp.2021.107873 Downloaded for Anonymous User (n/a) at Psykiatrisk Atdeling Augustenborg from Clinical Key.com by Elsevier on September

22, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

A. Gedebjerg, R.W. Thomsen, A.D. Kjaergaard et al.

are associated with risk of infection, this would suggest a causal role for MBL in the development of infection in type 2 diabetes.

2. Materials and methods

2.1. Study population

The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) cohort has been described in detail previously.¹⁸ Briefly, the DD2 cohort was initiated in November 2010 and is an ongoing cohort of patients recently diagnosed with type 2 diabetes.¹⁸ Enrollment has been continuous from hospital specialist outpatient clinics and general practitioners' offices. Hospital physicians and general practitioners identify newly/recently diagnosed patients with type 2 diabetes and complete an online questionnaire¹⁹ with health-related items (e.g., physical activity, alcohol consumption, and anthropometric measurements) and physical examination items (e.g., waist–hip ratio) for each participant at the time of DD2 enrollment. Fasting blood and urine samples are collected from each participant at enrollment and stored at —80C in the DD2 biobank.²⁰

2.2. Cohort definition

This observational, prospective cohort study comprised all DD2 participants, newly diagnosed with T2D, enrolled between November 2010 and December 2016 who gave their consent and had serum MBL levels and/or MBL expression genotypes available. A total of 7588 participants were enrolled in the study, but due to withdrawal of consent or lack of blood sample only 7305 participants were available for MBL serum measurement. DNA material was available for genetic analyses in a total of 3116 participant, but due to failed genotyping for one or more of the six SNPs in the *MBL2* gene only 3043 participants were genotyped for the six SNPs in the *MBL2* gene. A total of 2990 participants had both serum MBL and MBL genotypes (Supplementary Fig. 1).

2.3. Ethics

This study was approved by the Regional Committee on Health Research Ethics for Southern Denmark (record number S-20100082) and by the Danish Data Protection Agency (record number 2008-58-0035). All DD2 participants provided written informed consent.

2.4. Identification of hospital-treated infections

We identified hospital-treated infections occurring after the DD2 enrollment date based on all diagnoses (primary and secondary discharge diagnoses) recorded in the Danish National Registry of Patients. This Registry contains discharge diagnoses from all inpatient hospitalizations in Denmark since 1977 and from all emergency department visits and hospital outpatient clinic contacts since 1995.²¹ Discharge diagnoses are coded according to the International Classification of Diseases, Tenth Revision (Supplementary Table 1). In the current study, hospital-treated infections were classified into subtypes consistent with previous studies,^{22,23} i.e., bacterial infections, viral infections, and fungal infections. Bacterial diseases included pneumonia, urinary tract infections, skin infections, sepsis, abscesses, intra-abdominal infections, diarrheal diseases, and other bacterial infections. Viral diseases included influenza and other viral infections.

2.5. Identification of community-based antimicrobial prescriptions

We used the Danish Health Service Prescription Database to identify community-based antimicrobial prescriptions redeemed after the DD2 enrollment date. The Database contains information on all drugs prescribed to patients by either hospital or primary care based physicians and dispensed from any Danish pharmacy.²⁴ Antimicrobial

Journal of Diabetes and Its Complications xxx (xxxx) xxx

prescriptions were classified according to the Anatomical Therapeutic Chemical system (Supplementary Table 2). The prescriptions were classified into subtypes consistent with previous studies,²² i.e., dispensed prescriptions for all antimicrobial agents prescribed for oral treatment of bacterial, viral, and fungal infections. As a proxy for respiratory tract infections, we identified the number of prescriptions dispensed for oral treatment with phenoxymethylpenicillin (the recommended first-line treatment for respiratory tract infections in Denmark) and specific macrolides (erythromycin, roxithromycin, and clarithromycin).²² As a proxy for skin infections, we identified dispensed prescriptions for dicloxacillin and flucloxacillin.²² As a proxy for urinary tract infections, we used dispensed prescriptions for pivmecillinam, sulfamethizole, nitrofurantoin, and trimethoprim. Furthermore, we evaluated dispensed prescriptions for commonly prescribed broad-spectrum penicillin in Denmark (amoxicillin and amoxicillin with an enzyme inhibitor), which may be used for several infection types.²²

2.6. Serum MBL levels

Serum MBL levels are largely genetically determined, and therefore relatively stable over time.²⁵ Median serum MBL concentration in healthy Caucasians is 800–1000 μ g/L.²⁶ The DD2 biobank measured functional serum MBL levels at the time of enrolment using an inhouse time-resolved immuno-fluorometric assay, as described in detail elsewhere.²⁷ In brief, mannan-coated microtiter wells were incubated with serum samples, and bound MBL was detected with biotin-labeled monoclonal anti-MBL antibodies followed by europium-labeled streptavidin and detection using time-resolved fluorometry. The limit of quantification was 10 μ g/L and the intra-assay and inter-assay coefficients of variation were <10%.

2.7. MBL expression genotypes

Serum MBL levels vary widely between individuals mainly due to six common single nucleotide polymorphisms (SNPs) in the *MBL2* gene.²⁸ Three SNPs at codons 52, 54, and 57 of exon 1 are frequently referred to as variant D, B, and C, respectively, while the wild-type allele is referred to as allele A. Important SNPs in the promotor region are H/L and X/Y. Because of linkage disequilibrium, the six SNPs give rise to seven major haplotypes: HYPA, LYQA, LYPA, LXPA, LYPB, LYQC, and HYPD. These can be further combined into three MBL expression genotypes – low, intermediate, and high^{4,29} – corresponding to serum MBL levels.²⁸ TaqMan genotyping assays were used to genotype the six SNPs in the *MBL2* gene (rs11003125, rs7096206, rs7095891, rs5030737, rs1800451, and rs1800450) in the first 3043 consecutive patients in the DD2 cohort,²⁸ as described in detail elsewhere.³⁰

2.8. Covariates

From the online DD2 questionnaire¹⁹ and linked administrative and medical registries, we extracted information on covariates at the time of DD2 enrollment. Selection of covariates was based on their known association with serum MBL levels and/or risk of infections (Supplementary Table 3).

2.9. Biochemical analysis

High-sensitivity C-reactive protein (hs-CRP, mg/L) was determined by an in-house Time Resolved Immuno-fluorometric Assay, as previously described.³¹ Samples were diluted 1000-fold and measured in duplicate. Intra-assay and inter-assay coefficients of variation were < 5% and < 6%, respectively. HbA1c, fasting blood glucose, and lipids were measured using hospitals' routine analysis procedures.

2

Downloaded for Anonymous User (n/a) at Psykiatrisk Afdeling Augustenborg from ClinicalKey.com by Elsevier on September 22, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

<u>ARTICLE IN PRESS</u>

A. Gedebjerg, R.W. Thomsen, A.D. Kjaergaard et al.

2.10. Statistical analysis

We examined the association between serum MBL levels, as a continuous variable, and risk of outcomes using restricted cubic spline models with five degrees of freedom. In addition, serum MBL levels were categorized as low ($\leq 100 \ \mu g/L$), intermediate (101–1000 $\mu g/L$), or high (>1000 $\mu g/L$).³⁰ Consistent with previous findings suggesting an U-shaped association of MBL with mortality and vascular outcomes (i.e., that intermediate MBL levels may be the most advantageous^{30,32,33}), the intermediate serum MBL category (101–1000 $\mu g/L$) was used as reference.³⁰ The MBL expression genotypes were categorized into low, intermediate, or high, shown previously to correlate with serum MBL levels.^{30,34}

The cumulative incidence of hospital-treated infections and community-based antimicrobial prescriptions, with death as a competing risk, was plotted using STATA's stcompet command, and incidence rates were calculated using STATA's stptime command. Cox regression analysis, with time-on-study as time scale, was used to compute hazard ratios (HRs) and 95% confidence intervals (CIs) for outcomes. We detected no violations of the proportional hazards assumption.

We used three different adjustment models. In Model 1, HRs were adjusted for sex and age. In Model 2, HRs were adjusted for sex, age, diabetes duration, and levels of hs-CRP. In the fully adjusted Model 3, HRs were additionally adjusted for waist circumference, waist-hip ratio, body mass index, physical activity, smoking, alcohol consumption, comorbidities, fasting blood glucose level, HbA1c, total cholesterol level, low-density lipoprotein level, high-density cholesterol level, triglyceride level, and treatment with anti-diabetes and lipid-lowering agents. This extensive adjustment was to ensure robustness of potential associations between MBL levels and infections. Missing values for each covariate (n = 5-3966; 0.1%-54%; Table 1) were imputed, in order to create a complete dataset.³⁰ We did not impute MBL expression genotype when this information was missing (n = 4262; 58%).

In all analyses, since infections and antimicrobial prescriptions are generally common and repetitive events, we did not exclude individuals with a history of previous events prior to blood sampling (i.e., the DD2 enrollment date), assuming that most patients with an infectious

Table 1

Missing covariates for the serum MBL and MBL expression genotype cohorts within the DD2 cohort.

	Serum MBL cohort		MBL expression genotype cohort		
	Missing, n (%)	Total	Missing, n (%)	Total	
Sex	0 (0.0)	7305	0 (0.0)	3043	
Age	0 (0.0)	7305	0 (0.0)	3043	
Diabetes duration	0 (0.0)	7305	0 (0.0)	3043	
Waist circumference	13 (0.18)	7305	<5 ^b (0.2)	3043	
Waist-hip ratio	11 (0.15)	7305	$<5^{b}(0.2)$	3043	
BMI ^a	569 (7.79)	7305	245 (8.05)	3043	
Alcohol intake	0 (0.0)	7305	0 (0.0)	3043	
Physical activity	$<5^{b}(0.0)$	7305	0 (0.0)	3043	
Smoking ^a	1900 (26.01)	7305	612 (20.11)	3043	
CCI score	0 (0.0)	7305	0 (0.0)	3043	
Anti-diabetes drug use	0 (0.0)	7305	0 (0.0)	3043	
Lipid-lowering drug use	0 (0.0)	7305	0 (0.0)	3043	
Fasting blood glucose	2028 (27.76)	7305	368 (12.09)	3043	
HbA1c ^a	1548 (21.19)	7305	486 (15.97)	3043	
Total cholesterol ^a	3966 (54.29)	7305	1244 (40.88)	3043	
LDL cholesterol ^a	1763 (24.13)	7305	550 (18.07)	3043	
HDL cholestero ^a	3951 (54.09)	7305	1245 (40.91)	3043	
Triglycerides ^a	1849 (25.31)	7305	572 (18.80)	3043	
hs-CRP	5 (0.07)	7305	56 (1.84)	3043	

^a By August 2018, a total of 5847 DD2 patients (80%) in the serum MBL cohort and 2597 DD2 patients (85%) in the MBL genotype cohort had been linked to the Danish Diabetes Database for Adults.

^b Exact number of missing too low to be displayed according to Danish data protection regulations.

Journal of Diabetes and Its Complications xxx (xxxx) xxx

disease history would have fully recovered if they were able to attend the DD2 enrollment examination. We followed the patients from index date (i.e., DD2 enrollment date) until a first infection occurred (separately for hospital-diagnosed infections and antimicrobial prescriptions), emigration, death, or end of follow-up, whichever came first. We did not consider recurrent infectious events during follow-up in the analyses, due to relative short follow-up time and few events in the exposure groups (three categories). Instead, we display descriptive characteristics of recurrent event infections. For hospital-treated infections, end of follow-up was August 10, 2018. For community-based antimicrobial prescriptions, due to data availability the end of follow-up was December 31, 2017. Vital and emigration status, as well as exact dates of death, were obtained from the Danish Civil Registration System.³⁵

Hardy–Weinberg equilibrium was evaluated by a χ^2 test to assess risk of genotype misclassification. To evaluate the association between MBL expression genotype and serum MBL levels, we performed a Cuzick non-parametric test for trend and calculated R^2 using a simple linear regression.

2.11. Sensitivity analysis

We performed a sensitivity analysis excluding patients with serum CRP levels above 10 mg/L (n = 641; 9%) at time of enrollment, to eliminate those with possible ongoing infections and/or underlying autoimmune disease at the time of MBL testing.²³ Analyses were performed using STATA version 14.2.

3. Results

3.1. Baseline characteristics

The study included 7588 patients with type 2 diabetes, among whom 7305 (96%) had a serum MBL measurement available and 3043 (42%) were genotyped for the six SNPs in the MBL2 gene (Supplementary Fig. 1). The cohort was followed for up to 8 years, with a median follow-up of 4.5 years (inter-quartile range [IOR]: 3.0-5.5 years) for any hospital-treated infection and 1.5 years (IQR: 0.5-3.1 years) for the much more common event of any community-based antimicrobial prescription. 1140 patients (16%) were hospitalized with an infection and a total 5077 patients (70%) redeemed a community-based antimicrobial prescription. Supplementary Table 4 presents these events by patient subtype. During follow-up, a total of 14% of individuals experienced a bacterial infection-related hospitalization (relatively more males than females, Supplementary Table 5). Of these, 67% had only one, 20% had two, and 12% had three or more bacterial infectionrelated hospitalizations (Supplementary Table 5). Increasing number of hospitalizations was not associated with increased serum MBL levels, MBL expression genotype, or increased follow-up time (Supplementary Table 5). There was a step-wise increase in number of hospitalizations with increasing serum CRP levels and CCI (Supplementary Table 5).

There were no clear differences in baseline characteristics across different serum MBL and MBL expression genotype categories (Table 2, Supplementary Table 6).

The MBL genotype frequencies in type 2 diabetes patients were 15% for the low MBL expression genotype, 31% for the intermediate, and 55% for the high. Serum MBL levels were strongly associated with MBL expression genotypes (Supplementary Table 7, Supplementary Fig. 2; $R^2 = 0.31$, *P* for trend $<1 \times 10^{-300}$). Median serum MBL levels for patients with low, intermediate, and high MBL expression genotypes were 10 µg/L (IQR: 10–26 µg/L), 321 µg/L (IQR: 199–545 µg/L), and 1527 µg/L (IQR: 974–2394 µg/L). We detected no major deviations in Hardy-Weinberg equilibrium (Supplementary Table 8).

A. Gedebjerg, R.W. Thomsen, A.D. Kjaergaard et al.

Table 2

Characteristics of DD2 Cohort Participants at Baseline by Serum MBL Category.


	Low serum MBL (≤100 µg/L)	Intermediate serum MBL (101–1000 µg/L)	High serum MBL (>1000 μ g/L)
Total, N (%)	1295 (17.7)	2975 (40.7)	3035 (41.6)
Male sex, n (%)	727 (56.1)	1612 (54.2)	1939 (63.9)
Median age (IQR), years	61.6 (52.7-69.0)	61.9 (53.1-68.7)	62.3 (53.0-68.8)
Median diabetes duration (IQR), years	1.3 (0.3–2.9)	1.4 (0.4–2.9)	1.2 (0.3-2.9)
Median waist circumference (IQR), cm	106 (97–117)	107 (97–117)	105 (96-115)
Median waist-hip ratio (IQR)	0.98 (0.92-1.04)	0.98 (0.92-1.04)	0.98 (0.93-1.04)
Median body mass index (IQR), kg/m ²	30.5 (27.1-34.5)	30.7 (27.4-34.7)	29.7 (26.4-33.7)
High alcohol intake ^a , n (%)	74 (5.7)	211 (7.1)	190 (6.3)
Physical activity ^b (IQR), days/week	3 (2-7)	3 (2-7)	4 (2-7)
Smoking, n (%)			
Never	434 (45.5)	1039 (47.7)	1052 (46.3)
Former	351 (36.8)	749 (34.4)	750 (33.0)
Current	170 (17.8)	389 (17.9)	471 (20.7)
CCI score ^c , n (%)			
0	882 (68.1)	2034 (68.4)	2109 (69.5)
1–2	339 (26.2)	783 (26.3)	763 (25.1)
3	74 (5.7)	158 (5.3)	163 (5.4)
Anti-diabetes drug use, n (%)	1080 (83.4)	2547 (85.6)	2582 (85.1)
Lipid-lowering drug use, n (%)	932 (72.0)	2176 (73.1)	2037 (67.1)
Median fasting blood glucose level (IQR), mmol/L	7.1 (6.3-8.1)	7.1 (6.3-8.2)	7.2 (6.4-8.3)
Median HbA1c (IQR), mmol/mol	49 (44–55)	49 (43-55)	49 (44–56)
Median HbA1c (IQR), %	6.6 (6.2-7.2)	6.6 (6.1-7.2)	6.6 (6.2-7.3)
Median total cholesterol level (IQR), mmol/L	4.4 (3.8-5.2)	4.3 (3.7-5.1)	4.3 (3.7-5.1)
Median LDL cholesterol level (IQR), mmol/L	2.1 (1.7-2.7)	2.2 (1.7-2.8)	2.2 (1.7-2.9)
Median HDL cholesterol level (IQR), mmol/L	1.2 (1.0-1.4)	1.2 (1.0-1.4)	1.2 (1.0-1.5)
Median triglyceride level (IQR), mmol/L	1.7 (1.2–2.5)	1.7 (1.2–2.4)	1.6 (1.1-2.3)
Median hs-CRP level (IQR), mg/L	2.0 (0.8-4.7)	2.0 (0.9-4.5)	1.9 (0.8-4.3)

Abbreviations: MBL, mannose-binding lectin; IQR, interquartile range; CCI, Charlson Comorbidity Index; hs-CRP, high-sensitivity C-reactive protein.

Numbers of participants varied because of availability of data (see Table 1 for missing covariates).

^a High alcohol intake was defined as >14/21 alcoholic drinks/week for women/men. ^b Days per week with a minimum of 30 min of physical activity.

^c CCI (Charlson Comorbidity Index) score excluding diabetes.






Fig. 1. Time-to-event curves of any hospital-treated infections and any community-based antimicrobial prescriptions by serum MBL levels and MBL expression genotype categories. Cumulative incidence plots of any hospital-treated infections (A and B) and any community-based antimicrobial prescriptions (C and D) by serum MBL (A and C) and MBL expression genotype (B and D) categories. Cumulative incidence estimates are based on time from the DD2 enrollment date to the first event, with risk of death representing a competing risk.

4

<u>ARTICLE IN PRESS</u>

A. Gedebjerg, R.W. Thomsen, A.D. Kjaergaard et al.

Journal of Diabetes and Its Complications xxx (xxxx) xxx

3.2. Serum MBL and hospital-treated infections

Cumulative incidence curves and spline models showed an association of low serum MBL with increased risk of any hospital-treated infection (Figs. 1A & 2A). The L-shape of the spline model was preserved for hospital-treated bacterial infection (Fig. 2C) and most infection subtypes (pneumonia, urinary tract infections, diarrheal diseases, and other bacterial infections) but not for all (skin infections, intraabdominal, viral, and fungal infections) (Supplementary Fig. 3). Incidence rates are shown in Supplementary Table 9. Compared to the intermediate serum MBL category, the adjusted HR (Model 3) for the low serum MBL level was 1.13 (95% CI 0.96–1.33) for any infections, 1.19 (95% CI 1.01–1.41) for bacterial infections, 0.71 (95% CI 0.35–1.46) for viral infections, and 0.44 (95% CI 0.09–2.06) for fungal infections (Fig. 3). The association between low serum MBL levels and bacterial infections was primarily driven by pneumonia (aHR 1.30, 95% CI 0.98–1.70), diarrheal diseases (aHR 1.77, 95% CI 0.97–3.23), and other bacterial infections (aHR 1.50, 95% CI 1.00–2.24) (Fig. 4). Compared to the intermediate serum MBL category, high serum MBL was not associated with increased risk of any infection or subtypes.




Fig. 2. Risk of hospital-treated infections and community-based antimicrobial prescriptions by serum MBL levels. Any infections (A), bacterial infections (C), viral infections (E), fungal infections (G), any prescriptions (B), antibacterial prescriptions (D), antiviral prescriptions (F), and antifungal prescriptions (H). The solid lines indicate the hazard ratios and the dotted lines indicate 95% confidence intervals. Serum MBL as a continuous variable was modeled with five restricted cubic splines.

A. Gedebierg, R.W. Thomsen, A.D. Kiaergaard et al. Model 3 Model 3 HR(95% CI) HR(95% CI) Events/tota Events/total Serum MBL (µg/L) MBL expression genotype Any infections Any infections 217 / 1295 ≤100 1.13 (0.96-1.33) Low 95/446 1.08 (0.84-1.38) 101-1000 457 / 2975 1.00 192 / 939 1.00 Intermediate >1000 466 / 3035 1 01 (0 88-1 15) High 329 / 1658 0.98 (0.82-1.17) Bacterial infections Bacterial infections ю ≤100 207 / 1295 1.19 (1.01-1.41) 92/446 1.13 (0.88-1.46) Low 101-1000 415 / 2975 1.00 Intermediate 176 / 939 1.00 0.97 (0.80-1.16) >1000 429 / 3035 1.02 (0.89-1.17) 300 / 1658 High Viral infections Viral infections ≤100 10 / 1295 6/446 1.02 (0.38-2.71) 0.71 (0.35-1.46 Low 101-1000 33 / 2975 1.00 13 / 939 1.00 Intermediate >1000 0.95 (0.57-1.56) 1.07 (0.54-2.13) 31 / 3035 High 24 / 1658 **Fungal infections Fungal infections** ≤100 <5 / 1295 0.44 (0.09-2.06 0/446 Low 101-1000 10 / 2975 1.00 Intermediate 6 / 939 1.00 >1000 21 / 3035 1.91 (0.89–4.11) High 18 / 1658 1.96 (0.75-5.10) 0.5 0.5

Fig. 3. Hazard ratios of any hospital-treated infections, and bacterial, viral, and fungal infections by serum MBL levels and MBL expression genotype categories. Model 3 was adjusted for sex, age, diabetes duration, hs-CRP, waist circumference, waist-hip ratio, body mass index, physical activity, smoking, alcohol consumption, comorbidities, fasting blood glucose, HbA1c, total cholesterol, LDL, HDL, triglycerides, and use of anti-diabetes, and lipid-lowering drugs. Values for missing covariates were estimated using multiple imputation (Table 1).

However, the aHR for high serum MBL was particularly high 1.91 (95% CI 0.89–4.11) for fungal infections (Fig. 3).

3.3. MBL expression genotype and hospital-treated infections

Cumulative incidence curves showed that the low MBL expression genotype was associated with increased risk of any hospital-treated infection (Fig. 1B). Incidence rates are shown in Supplementary Table 9.

Compared to the intermediate MBL expression genotype, the adjusted HR (Model 3) for the low MBL expression genotype was 1.08 (95% CI 0.84-1.38) for any infections, 1.13 (95% CI 0.88-1.46) for bacterial infections, and 1.02 (95% CI 0.38-2.71) for viral infections (Fig. 3). Infection subtype analyses showed a clear association between low MBL expression genotype and diarrheal diseases (aHR 2.23, 95% CI 1.04–4.80) (Fig. 4). Compared to the intermediate MBL genotype expression category, high genotype expression was not associated with increased risk of any infections or subtypes. However, the aHR for high MBL expression genotype was particularly high 1.96 (95% CI 0.75–5.10) for fungal infections (Fig. 3).

3.4. Serum MBL and antimicrobial prescriptions

Cumulative incidence curves and spline models showed no clear association of low serum MBL with increased risk of any antimicrobial prescriptions (Figs. 1C & 2B), including antibacterial, antiviral, and antifungal prescriptions (Fig. 1, Supplementary Fig. 4). Incidence rates are shown in Supplementary Table 9.

Compared to the intermediate serum MBL category, the adjusted HR (Model 3) for low serum MBL was 1.06 (95% CI 0.98-1.15) for any antimicrobial prescriptions, 1.07 (95% CI 0.99-1.16) for antibacterial prescriptions, 0.73 (95% CI 0.54-0.99) for antiviral prescriptions, and 1.07

(95% CI 0.88-1.30) for antifungal prescriptions (Fig. 5). Results for individual subtypes of antibacterial prescriptions were similar (Fig. 6). Compared to intermediate MBL levels, the adjusted HRs (Model 3) for antiviral prescriptions were 0.73 (95% CI 0.54-0.99) for the low serum MBL category and 0.63 (95% CI 0.50-0.81) for the high serum MBL category. Additionally, high serum MBL was associated with increased risk of antifungal prescriptions with an aHR of 1.17 (1.01–1.36) (Fig. 5).

3.5. MBL expression genotype and antimicrobial prescriptions

Cumulative incidence curves showed that the low MBL expression genotype patients tended to have the highest risk of any antimicrobial prescriptions (Fig. 1D). Incidence rates are shown in Supplementary Table 9.

Compared to the intermediate MBL expression genotype, the aHR (Model 3) for the low MBL expression genotype was 1.18 (95% CI 1.04–1.34) for any antimicrobial prescriptions, 1.20 (95% CI 1.05–1.36) for antibacterial, 1.10 (95% CI 0.70-1.72) for antiviral, and 0.90 (95% CI 0.66–1.21) for antifungal prescriptions (Fig. 5). The risk estimate was highest for prescriptions for skin infections (aHR 1.22, 95% CI 0.97-1.53) (Fig. 6). An additional finding was that the high MBL expression genotype was also associated with a slightly increased risk of any antimicrobial prescriptions (aHR 1.10, 95% CI 1.00-1.20) and antibacterial prescriptions (aHR 1.11, 95% CI 1.02-1.22) (Fig. 5).

3.6. Sensitivity analyses

Overall, the sensitivity analyses restricted to patients with a CRP level below 10 mg/L (Supplementary Figs. 5–16) yielded results similar to those in the main analyses.

6

Journal of Diabetes and Its Complications xxx (xxxx) xxx

A. Gedebjerg, R.

(xxxx) xxx

R.W. Thomsen, A.D. I	Kjaergaard et al.					Journal of Diabetes an	d Its Complications xxx (
		Model 3 HR (95% CI)				Model 3 HR (95% CI)	
	Events/total	;			Events/total		
Serum MBL (µ	g/L)			MBL expressio	n genotype		
Pneumonia				Pneumonia			
≤100	80 / 1295	I+●-1	1.30 (0.98–1.70)	Low	34/446	⊢ ∳ -1	1.09 (0.72–1.67)
101–1000	145/2975	ļ	1.00	Intermediate	63/939	Ļ	1.00
>1000	165 / 3035	r∳-i I	1.06 (0.85–1.34)	High	122 / 1658	⊦ <mark>⊨</mark> ⊣ ∣	1.11 (0.82–1.51)
Urinary tract in	fection	Ì		Urinary tract inf	fection	Ì	
≤100	48 / 1295	⊢ ⊷ ⊣	1.14 (0.81–1.62)	Low	18/446	⊢┥	0.94 (0.54–1.64)
101–1000	98/2975	,	1.00	Intermediate	42/939	Ļ	1.00
>1000	101/3035	r∳-i	1.06 (0.80–1.40)	High	66 / 1658	⊦∎¦⊣ ∣	0.89 (0.60–1.31)
Skin infection		1		Skin infection		I	
≤100	44 / 1295	ı ⊨	1.11 (0.78–1.60)	Low	15/446	⊢┥┤	0.92 (0.51–1.68)
101–1000	95/2975	4	1.00	Intermediate	40/939	Å	1.00
>1000	82/3035	⊦≜¦⊣ │	0.89 (0.66–1.21)	High	71/1658	⊦∳⊣	1.02 (0.69–1.51)
Sepsis		1		Sepsis			
≤100	36 / 1295	⊢∳⊣	1.06 (0.72–1.58)	Low	19/446	⊢ ∳ ⊸i	1.09 (0.62–1.91)
101–1000	79/2975	ļ	1.00	Intermediate	36/939		1.00
>1000	86/3035	r þ -i	1.08 (0.79–1.47)	High	66 / 1658	⊦∳⊣	1.00 (0.66–1.51)
Abscess		1		Abscess			
≤100	34 / 1295	⊢∳⊣	1.00 (0.67–1.49)	Low	10/446	⊢●┤	0.65 (0.32–1.33)
101–1000	80/2975	+	1.00	Intermediate	36/939	+	1.00
>1000	85/3035	۲ ۴ -۱	1.09 (0.80–1.49)	High	70 / 1658	┝╈┥	1.14 (0.76–1.71)
Intra abdomin	al infection			Intra abdomina	al infection		
≤100	32 / 1295	⊦₁●₋⊣	1.17 (0.77–1.80)	Low	12/446	⊢∙¦	0.73 (0.38–1.42)
101–1000	63/2975	Ý	1.00	Intermediate	34/939	+	1.00
>1000	60/3035	н	0.88 (0.62–1.26)	High	45 / 1658	۲	0.72 (0.46–1.14)
Diarrheal dise	ase			Diarrheal disea	ase		
≤100	19 / 1295	j → I	1.77 (0.97–3.23)	Low	14/446		42.23 (1.04–4.80)
101–1000	25/2975	Ý	1.00	Intermediate	13/939	, t	1.00
>1000	40/3035	⊢ ∙-1	1.67 (1.00–2.77)	High	28 / 1658	⊢i•1	1.21 (0.62–2.34)
Other bacteria	l infection	1		Other bacterial	infection		
≤100	39 / 1295	j•-1	1.50 (1.00–2.24)	Low	13/446	⊢	0.91 (0.47–1.77)
101–1000	62/2975	Ť	1.00	Intermediate	29/939	•	1.00
>1000	58 / 3035	. ⊢•i-i	0.93 (0.64–1.34)	High	43 / 1658		0.83 (0.51–1.33)
		0.5 1 2 4	1			0.5 1 2 4	1

Fig. 4. Hazard ratios of hospital-treated bacterial infection subtypes by serum MBL levels and MBL expression genotype categories. Model 3 was adjusted for sex, age, diabetes duration, hs-CRP, waist circumference, waist-hip ratio, body mass index, physical activity, smoking, alcohol consumption, comorbidities, fasting blood glucose, HbA1c, total cholesterol, LDL, HDL, triglycerides, and use of anti-diabetes, and lipid-lowering drugs. Values for missing covariates were estimated using multiple imputation (Table 1).

A. Gedebjerg, R.W. Thomsen, A.D. Kjaergaard et al.

Journal of Diabetes and Its Complications xxx (xxxx) xxx

					-	-		
	Events/total	Model 3 HR(95% CI)			Events/total	Model 3 HR(95% CI)		
Serum MBL (µg/L	_)			MBL expression	genotype			
Any prescriptions	3	l		Any prescription	6	1		
≤100	924 / 1295	P	1.06 (0.98–1.15)	Low	367 / 446	l I⊕I	1.18 (1.04–1.34)	
101–1000	2068 / 2975	Ļ	1.00	Intermediate	737 / 939	•	1.00	
>1000	2085 / 3035	, i	1.01 (0.95–1.07)	High	1330 / 1658	e	1.10 (1.00–1.20)	
		İ				i		
Antibacterial prescriptions				Antibacterial pres	Antibacterial prescriptions			
≤100	887 / 1295	lei	1.07 (0.99–1.16)	Low	355 / 446	liei	1.20 (1.05–1.36)	
101–1000	1974 / 2975	•	1.00	Intermediate	714 / 939	•	1.00	
>1000	1994 / 3035		1.02 (0.96–1.08)	High	1288 / 1658		1.11 (1.02–1.22)	
		l						
Antiviral prescriptions			Antiviral prescriptions					
≤100	56 / 1295	⊢ ●	0.73 (0.54–0.99)	Low	29 / 446	⊢ −−1	1.10 (0.70–1.72)	
101–1000	174 / 2975	÷	1.00	Intermediate	57 / 939	+	1.00	
>1000	110 / 3035	⊢•⊣ ¦	0.63 (0.50-0.81)	High	80 / 1658	⊢• <u> </u>	0.79 (0.56–1.12)	
		Ì				Ì		
Antifungal prescriptions			Antifungal presc	riptions				
≤100	149 / 1295	Ļ ⊨ ⊣	1.07 (0.88–1.30)	Low	62 / 446	⊢●┤	0.90 (0.66–1.21)	
101–1000	328 / 2975	↓ I	1.00	Intermediate	147 / 939	•	1.00	
>1000	368 / 3035		1.17 (1.01–1.36)	High	233 / 1658	+	0.89 (0.72–1.09)	_
		0.5 1 2				0.5 1 2		

Fig. 5. Hazard ratios of any community-based antimicrobial prescriptions, and antibacterial, antiviral, and antifungal prescriptions by serum MBL levels and MBL expression genotype categories. Model 3 was adjusted for sex, age, diabetes duration, hs-CRP, waist circumference, waist–hip ratio, body mass index, physical activity, smoking, alcohol consumption, comorbidities, fasting blood glucose, HbA1c, total cholesterol, LDL, HDL, triglycerides, and use of anti-diabetes, and lipid-lowering drugs. Values for missing covariates were estimated using multiple imputation (Table 1).

4. Discussion

In this cohort study of 7305 patients recently diagnosed with type 2 diabetes, we found evidence that genetically low MBL is a weak causal risk factor for developing infectious disease.

Our findings corroborate and extend findings from a previous Danish cohort study of 9245 individuals from the general population followed for up to 24 years.³ This study found relative risks in the range of 1.1 to 1.7 for a number of infectious diseases (e.g., pneumonia and diarrheal diseases) associated with low versus high MBL expression genotype.³ Even though MBL is a pivotal factor in the innate immune system, initiating the complement cascade and promoting pathogen clearance,^{26,27} the many redundant effector functions of the immune systems, e.g., other soluble pattern recognition molecules such as ficolins, may be able to compensate for the function of MBL in adults with MBL deficiency.³ Accordingly, it has been suggested that MBL deficiency may only increase risk of infections when other parts of the immune system are compromised,⁸ e.g., by chemotherapy,¹³ autoimmune and inflammatory diseases such as diabetes, or cancer.¹² MBL deficiency in combination with type 2 diabetes may act as a dual hit to the immune system and thus increase the susceptibility of infections. We found that low MBL was a relatively weak risk factor for developing infections in type 2 diabetes, mostly driven by a slightly increased risk for bacterial infections, with a stronger signal for diarrheal diseases in particular. However, our findings do not suggest that MBL deficiency is of substantial clinical relevance in relation to vulnerability to infections. Recurrent infections, with chronic diarrhea as the most common complaint, has been associated with MBL deficiency in a small study of 104 patients.³⁶ We found no indication of an association between MBL deficiency and recurrent hospital-treated bacterial infections. This accords with a case-control study of 120 MBL-deficient adults showing that individuals with the low MBL expression genotype were more likely to suffer from gastrointestinal disease than individuals with the intermediate or high MBL expression genotype.³⁷ The participants in the DD2 cohort are newly diagnosed with type 2 diabetes with a median diabetes duration 1.3 years, one could speculate that risk of infection may increase with diabetes duration or concomitant complications.

As an additional finding, we found that high serum MBL and corresponding high MBL expression genotype were compatible with a twofold increased risk of hospital-treated fungal infections. MBL binds to different fungal pathogens through carbohydrate ligands such as mannan.^{2,38} In patients in a high-risk intensive-care unit no association between low or high MBL levels and Candida colonization and intraabdominal candidiasis were found.³⁹ Thus, further studies are needed to address a possible causal association between MBL and fungal infections.

Main strengths of this large nationwide cohort study include the assessment of detailed covariates and outcomes available in the DD2 database, DD2 biobank, and by linkage with high-quality population-based health registries.⁴⁰ These resources provide nearly 100% completeness for serum MBL and complete follow-up for outcome events, both when defining an infectious disease event as a hospital contact due to infection and as a redeemed prescription for an antimicrobial agent.

Limitations of this study include the possibility of survival bias and selection bias for patients with certain MBL levels and outcome risks before entering the DD2 cohort. Such bias would likely lead to decreased participation of patients with a severe type 2 diabetes phenotype or high infectious disease risk and likely bias results towards the null hypothesis. Of note, age, demographic characteristics, diabetes characteristics and comorbidities of early type 2 diabetes patients in the DD2 cohort are very similar to those of patients with early treated type 2 diabetes in everyday clinical practice in Denmark.^{18,41} Misclassification of

A. Gedebjerg, R.W. Thomsen, A.D. Kjaergaard et al.

Journal of Diabetes and Its Complications xxx (xxxx) xxx




Fig. 6. Hazard ratios of community-treated prescription subtypes by serum MBL levels and MBL expression genotype categories. Model 3 was adjusted for sex, age, diabetes duration, hs-CRP, waist circumference, waist–hip ratio, body mass index, physical activity, smoking, alcohol consumption, comorbidities, fasting blood glucose, HbA1c, total cholesterol, LDL, HDL, triglycerides, and use of anti-diabetes, and lipid-lowering drugs. Values for missing covariates were estimated using multiple imputation (Table 1).

<u>ARTICLE IN PRESS</u>

A. Gedebjerg, R.W. Thomsen, A.D. Kjaergaard et al.

diagnoses, prescriptions, or genotypes in our cohort may have happened. However, the validity of major diagnoses in our registries, including for infectious disease diagnoses is high,⁴² and the MBL genotype frequencies were similar to frequencies in the general population³ and in patients with type 1 diabetes.²⁶ Another potential limitation is that prescribed antimicrobial drugs are only a proxy for true presence of infection. In the community setting, antimicrobial agents might be prescribed outside their proper indication, and general practitioners' approach to treating infectious diseases may vary,²² which may have resulted in some outcome misclassification. However, we expect such misclassification to be non-differential as regards the patients' MBL level, likely biasing results towards the null hypothesis. Yet another potential limitation is that we did not account for autoimmune diseases, which are associated with increased risk of infection. However, excluding patients with serum CRP levels above 10 mg/L, to eliminate those with possible ongoing infections and/or autoimmune disease at time of blood sampling did not alter the results, and thus cannot explain our findings. Finally, due to our relatively low sample size and thus low precision (i.e., wide 95% CI), we acknowledge that we lack power to show robust results. However, as several point estimates were compatible with an association and may be biologically plausible, our findings justify and encourage future efforts in investigating the role of MBL in the development of and/or predisposition to infections. Indeed, we have previously shown that MBL may be clinically important in patients with T2D, since patients with low as well as high serum MBL have an increased risk of cardiovascular events, and thus may benefit from a more aggressive preventative treatment.³⁰

In conclusion, this cohort study supports that genetically low MBL is a weak causal risk factor for infections in patients with type 2 diabetes. A possible role of low MBL in causing bacterial infections and diarrheal diseases in particular in patients with type 2 diabetes merits further studies.

CRediT authorship contribution statement

H.B.N., H.T.S., and J.R. participated in planning and designing the parent DD2 project cohort study. R.W.T, A.D.K., J.S.N., J.R., S.F., I.B., H.B.N., H.T.S., T.K.H., and M.B. designed the current study. M.B. was responsible for serum MBL and hs-CRP measurements, and R.S. was responsible for MBL genotyping. I.B. was responsible for obtaining data from the biobank and overseeing the other biochemical analyses. A.G., A.D.K., and R.W.T. participated in the design of the current study, and A.G. performed the statistical analyses. A.G. drafted the article, with help from A.D.K., R.W.T., and M.B. All other authors have critically reviewed the manuscript. All authors contributed substantially to the study, revised the manuscript for intellectual content, and approved the final version to be submitted. A.G., R.W.T., and M.B. are the guarantors of this work and, as such, had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analyses.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgement

We are grateful to all participants in the DD2 study. We thank Hanne Petersen and Karen Mathiassen for their assistance with the large-volume measurements of serum MBL and hs-CRP. We gratefully acknowledge Sia Kromann Nicolaisen for assistance with data management.

Funding

This work was supported by The Danish Centre for Strategic Research in Type 2 Diabetes Project (DD2) which is supported by the

Journal of Diabetes and Its Complications xxx (xxxx) xxx

Danish Agency for Science [grant nos. 09-067009 and 09-075724], the Danish Health and Medicines Authority, the Danish Diabetes Association, and an unrestricted donation from Novo Nordisk A/S. Project partners are listed on the www.DD2.nu website. The work of A.G. was supported by the Danish Diabetes Academy, which is funded by an unrestricted grant from the Novo Nordisk Foundation, and by grants from the Danish Heart Foundation [grant nos. 15-R99-A5866-22891] and Aarhus University. In addition, A.G. has received funding from the Aase and Ejnar Danielsen Foundation, Augustinus Foundation, A.P. Møller Foundation, Hertz Foundation, and Bønnelycke Foundation. The Department of Clinical Epidemiology, Aarhus University Hospital, participates in the International Diabetic Neuropathy Consortium research program, which is supported by a Novo Nordisk Foundation Challenge program grant [grant number NNF14SA000 6]. The funding sources had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Prior presentation

This study was presented as a poster presentation at the annual virtual meeting of the European Association for the Study of Diabetes (EASD), 21-25 September, 2020.

Author statement

All authors have seen and approved the content, have contributed significantly to the work, and fulfill the criteria given in the Authorship paragraph.

The article is the authors' original work.

The authors did not receive any writing assistance or copy editing outside the author group.

The manuscript has not been submitted or accepted for publication elsewhere.

References

- Ezekowitz RA. Role of the mannose-binding lectin in innate immunity. J Infect Dis 2003;187:S335-9.
- Eisen DP, Minchinton RM. Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin Infect Dis 2003;37:1496-505.
- Dahl M, Tybjaerg-Hansen A, Schnohr P. Nordestgaard BG. A population-based study of morbidity and mortality in mannose-binding lectin deficiency. J Exp Med 2004;199:1391-9.
- Eisen DP, Dean MM, Boermeester MA, et al. Low serum mannose-binding lectin level increases the risk of death due to pneumococcal infection. Clin Infect Dis 2008;47: 510-6.
- Garcia-Laorden MI, Sole-Violan J, Rodriguez de Castro F, et al. Mannose-binding lectin and mannose-binding lectin-associated serine protease 2 in susceptibility, severity, and outcome of pneumonia in adults. *The Journal of allergy and clinical immunology*. 2008;122(2): 368–374, 374.e361–362.
- Ip WK, Chan KH, Law HK, et al. Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection. J Infect Dis 2005;191:1697-704.
- Roy S, Knox K, Segal S, et al. MBL genotype and risk of invasive pneumococcal disease: a case-control study. Lancet 2002;359:1569-73.
- Eisen DP. Mannose-binding lectin deficiency and respiratory tract infection. J Innate Immun 2010;2:114-22.
- Rantala A, Lajunen T, Juvonen R, et al. Mannose-binding lectin concentrations, MBL2 polymorphisms, and susceptibility to respiratory tract infections in young men. J Infect Dis 2008;198:1247-53.
- Zhang H, Zhou G, Zhi L, et al. Association between mannose-binding lectin gene polymorphisms and susceptibility to severe acute respiratory syndrome coronavirus infection. J Infect Dis 2005;192:1355-61.
- Garred P, Voss A, Madsen HO, Junker P. Association of mannose-binding lectin gene variation with disease severity and infections in a population-based cohort of systemic lupus erythematosus patients. Genes Immun 2001;2:442-50.
- Neth O, Hann I, Turner MW, Klein NJ. Deficiency of mannose-binding lectin and burden of infection in children with malignancy: a prospective study. Lancet 2001;358:614-8.
- Peterslund NA, Koch C, Jensenius JC, Thiel S. Association between deficiency of mannose-binding lectin and severe infections after chemotherapy. Lancet 2001;358: 637-8.
- 14. Super M, Thiel S, Lu J, Levinsky RJ, Turner MW. Association of low levels of mannanbinding protein with a common defect of opsonisation. Lancet 1989;2:1236-9.
- Garred P, J JS, Quist L, Taaning E, Madsen HO. Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome. J Infect Dis 2003;188:1394-403.

A. Gedebjerg, R.W. Thomsen, A.D. Kjaergaard et al.

- Mor A, Berencsi K, Nielsen JS, et al. Rates of community-based antibiotic prescriptions and hospital-treated infections in individuals with and without type 2 diabetes: a Danish Nationwide Cohort Study, 2004–2012. *Clin Infect Dis.* 2016;63(4): 501–511.
- 17. Reilev M, Kristensen KB, Pottegård A, et al. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. Int J Epidemiol 2020;49(5): 1468-81.
- Christensen DH, Nicolaisen SK, Berencsi K, et al. Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project cohort of newly diagnosed patients with type 2 diabetes: a cohort profile. BMJ Open 2018;8, e017273.
- Nielsen JS, Thomsen RW, Steffensen C, Christiansen JS. The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) study: implementation of a nationwide patient enrollment system. Clin Epidemiol 2012;4:27-36.
- Christensen H, Nielsen JS, Sorensen KM, Melbye M, Brandslund I. New national biobank of the Danish Center for Strategic Research on Type 2 Diabetes (DD2). Clin Epidemiol 2012;4:37-42.
- Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality. and research potential Clin Epidemiol 2015;7:449-90.
- 22. Kaspersen KA, Dinh KM, Erikstrup LT, et al. Low-grade inflammation is associated with susceptibility to infection in healthy men: results from the Danish Blood Donor Study (DBDS). PLoS One 2016;11, e0164220.
- **23.** Zacho J, Benfield T, Tybjaerg-Hansen A, Nordestgaard BG. Increased baseline C-reactive protein concentrations are associated with increased risk of infections: results from 2 large Danish population cohorts. Clin Chem 2016;62:335-42.
- Johannesdottir SA, Horvath-Puho E, Ehrenstein V, Schmidt M, Pedersen L, Sorensen HT. Existing data sources for clinical epidemiology: the Danish National Database of Reimbursed Prescriptions. Clin Epidemiol 2012;4:303-13.
- 25. Ytting H, Christensen IJ, Thiel S, et al. Biological variation in circulating levels of mannan-binding lectin (MBL) and MBL-associated serine protease-2 and the influence of age. gender and physical exercise Scand J Immunol 2007;66:458-64.
- 26. Hansen TK, Tarnow L, Thiel S, et al. Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes 2004;53:1570-6.
- Thiel S, Moller-Kristensen M, Jensen L, Jensenius JC. Assays for the functional activity of the mannan-binding lectin pathway of complement activation. Immunobiology 2002;205:446-54.
- Molle I, Steffensen R, Thiel S, Peterslund NA. Chemotherapy-related infections in patients with multiple myeloma: associations with mannan-binding lectin genotypes. Eur J Haematol 2006;77:19-26.

Journal of Diabetes and Its Complications xxx (xxxx) xxx

- Swale A, Miyajima F, Kolamunnage-Dona R, et al. Serum mannose-binding lectin concentration, but not genotype, is associated with Clostridium difficile infection recurrence: a prospective cohort study. Clin Infect Dis 2014;59:1429-36.
- Gedebjerg A, Bjerre M, Kjaergaard AD, et al. Mannose-binding Lectin and risk of cardiovascular events and mortality in type 2 diabetes: a Danish Cohort Study. Diabetes Care 2020;43(9):2190-8.
- Holt CB, Ostergaard JA, Thiel S, et al. Circulating lectin pathway proteins do not predict short-term cardiac outcomes after myocardial infarction. Clin Exp Immunol 2019;198 (1):94-100.
- Eisen DP, Osthoff M. If there is an evolutionary selection pressure for the high frequency of MBL2 polymorphisms, what is it? Clin Exp Immunol 2014;176:165-71.
- Tomaiuolo R, Ruocco A, Salapete C, et al. Activity of mannose-binding lectin in centenarians. Aging Cell 2012;11:394-400.
- Gadjeva M, Takahashi K, Thiel S. Mannan-binding lectin—a soluble pattern recognition molecule. Mol Immunol 2004;41:113-21.
- Schmidt M, Pedersen I, Sorensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 2014;29:541-9.
- Rashidi E, Fazlollahi MR, Zahedifard S, et al. Mannose-binding lectin deficiency in patients with a history of recurrent infections. Iran J Allergy Asthma Immunol 2016;15: 69-74.
- Bjarnadottir HTV, Jorgensen GH, Arnardottir M, Ludviksson BR. Mannan-binding Lectin (MBL) deficient individuals with the O/O genotype are highly susceptible to gastrointestinal diseases. J Clin Cell Immunol 2014;5:182.
- 38. Ip WK, Lau YL. Role of mannose-binding lectin in the innate defense against Candida albicans: enhancement of complement activation, but lack of opsonic function, in phagocytosis by human dendritic cells. J Infect Dis 2004;190:632-40.
- 39. Osthoff M, Wojtowicz A, Tissot F, et al. Association of lectin pathway proteins with intra-abdominal Candida infection in high-risk surgical intensive-care unit patients. A prospective cohort study within the fungal infection network of Switzerland. J Infect 2016;72:377-85.
- Schmidt M, Schmidt SAJ, Adelborg K, et al. The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol 2019;11:563-91.
- 41. Gedebjerg A, Almdal TP, Berencsi K, et al. Prevalence of micro- and macrovascular diabetes complications at time of type 2 diabetes diagnosis and associated clinical characteristics: a cross-sectional baseline study of 6958 patients in the Danish DD2 cohort. J Diabetes Complications 2018;32(1):34-40.
- Henriksen DP, Nielsen SL, Laursen CB, Hallas J, Pedersen C, Lassen AT. How well do discharge diagnoses identify hospitalised patients with community-acquired infections?—a validation study. PLoS One 2014;9, e92891.